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Figure S1A. H1299 cells were transfected with pGL3basic, HDMXP2luc01 (black 
bars) or HDMXP2luc01Δp53RE (white bars) along with increasing amounts of 
pc53SN3. Luciferase was determined 48h following transfection. Results are 
expressed as a percentage of activity in HDMXP2luc01 only transfected cells 
(mean±s.e.m.). Data are pooled from two independent experiments of duplicate 
transfections each. 
 
Figure S1B. H1299 cells were transfected with HDMXP2luc01 (black bars), p21-luc 
(pale gray bars), bax-luc (white bars) or HDM2luc01 (dark gray bars). (i) Basal 
luciferase activities of each reporter plasmid are shown, expressed as RLU. (ii) 
Activity in cells co-transfected with increasing amounts of wt p53 are shown, 
expressed as a percentage of activity in cells with no p53 co-transfected 
(mean±s.e.m.). Data are pooled from two independent experiments of duplicate 
transfections each (n=4). 
 
Figure S2A.  Testicular germ cell tumor cell lines N-TERA-2 and 833KE were 
treated with Nutlin-3 (10 µM) for 8 and 24 hrs. Cells were harvested, and RNA and 
protein extracts were isolated. Expression of the indicated mRNAs and proteins was 
investigated by RT-PCR and Western blotting. 
 
Figure S2B. Uveal melanoma cell line Mel285, stably expressing either control 
shRNA or p53 shRNA were treated with Nutlin-3 (10 µM) for 24 hrs. Cells were 
harvested and total RNA isolated. Expression of HDMX-P2 and p21WAF1 was 
investigated by real-time RT-PCR.  
 
Figure S2C. The U2OS cells containing IPTG-inducible p14ARF (NARF cells) were 
mock treated or treated with IPTG for indicated period of time. Expression of 
p14ARF was monitored by immunofluorescence with anti-p14ARF monoclonal 
antibody 4C6. Nuclei were stained with DAPI. 
 
Figure S2D. Ovarian cancer cell lines, and normal cells were exposed to 10 μM 
Cisplatin and cells analysed by RT-qPCR at time points after 24 h of treatment.  The 
fold induction of HDMX-P2 and HDM2-P2 transcripts are shown.  n.d. = not 
detectable. 
 
Figure S2E. Breast cancer cell lines ZR75-30 and MPE600 (both wild-type p53) and 
osteosarcoma cell lines U2OS (wild-type p53) and SAOS-2 (p53-null) were treated 
for the indicated periods with Leptomycin B (LMB; 10 nM), Etoposide (10 µM), 
Nutlin-3 (10 µM) or Neocarzinostatin (NCS; 200 ng/ml). Expression of the indicated 
mRNAs was investigated by RT-PCR.  
 
Figure S2F. MCF-10A breast epithelial cells (M1) and its oncogenic-Ras transformed 
derivative (M2), the last either expressing control shRNA or p53-shRNA, were 
treated with RITA (1 µM) for indicated periods. Expression of the indicated mRNAs 
was investigated by RT-PCR.  
 
Figure S3A. Mouse embryo fibroblasts transiently transduced with lentiviruses 
expressing either control shRNA of p53-shRNA were either mock-treated or 
irradiated with 10 Gy. RNA and protein was isolated at indicated time-points and 
expression of the mdmx and gapdh mRNAs was investigated by RT-PCR and protein 
analysis was performed by Western blotting. The DNA damage response was 
monitored by investigating the phosphorylation of KAP1 (P-S824 KAP1). 
 
Figure S3B. Mouse embryo fibroblasts, wild-type or p53-null, were treated with 
Etoposide (20 µM) or Nutlin-3 (10 µM) for indicated periods. RNA and protein were 
harvested and investigated by RT-PCR and Western blotting. The DNA-damage 
response was monitored by investigating the phosphorylation of KAP1 (P-S824 
KAP1). 
 
Figure S4A. MCF-7 cells in 6-well plates were transfected with 250 ng pEGFP-N1 
and the indicated amounts of tagged HDMX expression plasmids 48 h before HDMX 
and GFP expression were determined by Western blotting.   
 
Figure S4B.  U2OS cells were transfected with either HA-HDMX or HA-HDMX-L 
expression vectors. Next day, cells were either mock-treated or treated with Etoposide 
(20 µM) for 4 hrs, fixated with 4% paraformaldehyde and processed for 
immunofluorescence. HDMX expression was investigated with anti-HDMX antibody 
6B1A. DNA damage response was monitored with anti-γ-H2AX, and nuclei were 
stained with DAPI.  
 
Figure S4C.  H1299 cells in 60 mm dishes were transfected with 670 ng pHis6Ub, 85 
ng pEGFP-N1, 670 ng each of the indicated HDM2 and HDMX expression vectors 
and pcDNA3.1 vector to a total of 3085 ng.  24 h later cells were lysed for western 
blotting. 
 
Figure S4D. MCF-7 cells were transfected with 500 ng HA-HDMX or HA-HDMX-L 
expression vectors (lanes 1, 3 and 2, 4, respectively), in the absence of presence of 
100 ng HDM2-expression vector (lanes 1,2 and 3,4, respectively), or with empty 
vector (lanes 5), all in the presence of 1 µg His6-Ub expression vector. Next day cells 
were all treated with MG-132 (20 µM), and were indicated NCS (200 ng/ml) was 
added 30 minutes later. Cells were harvested 5 hrs later, and processed for in vivo 
ubiquitination assay and total cell extracts.  
 
Figure S4E. 174-2 cells were transfected in 6-well plates; amounts of the indicated 
plasmids were directly scaled up from the 96-well plate reporter assays in Fig. 4D (1X 
≡ 100 ng).  EGFP vector was included to verify transfection efficiency.  Cells were 
harvested 48 h after transfection. 
 
Figure S4F. MCF-7 cells were transfected with HA-HDMX and HA-HDMX-L 
expression vectors. Transfected cells were selected for neomycin-resistance and 
monoclonal cell lines were established. Cell extracts were analyzed by Western 
blotting. HDMX expression was investigated both by using anti-HDMX antibody, 
which also detects endogenous HDMX and by using anti-HA which only detects 
ectopically expressed HDMX 
 
Figure S5A.  MCF-7 cells were transfected with siRNA to HDMX exon 1β (HDMXP2), ctr1-
1 and ctrl-2 siRNAs, which differ from HDMXP2 siRNA by 4 bases in the seed and central 
regions respectively, and scrambled control siRNA.  48 h later cells were exposed to 0 or 5 
Gy ionizing radiation and cells were harvested 6 h later.  RT-PCR and western blots show 
results from a representative of three independent experiments.  Quantification show 
mean±SEM changes in protein abundance for the three experiments.  Open bars: 0 Gy; closed 
bars: 5 Gy.  
 
Figure S5B.  Quantification of HDM2 and p21WAF1 protein abundance from the 
experiments shown in Fig. 5A. Open bars, control; closed bars, 5 Gy. 
 
Figure S5C. MRC5-hTERTneo were exposed 5 Gy ionizing radiation and harvested 
at the indicated times prior to analysis by western blotting (lower panel).  Upper panel 
shows that exposure to ionizing radiation does not induce HDMX-P2 mRNA in these 
cells, in contrast to MCF-7 cells (6 h time point). 
 
Figure S5D. MCF-7 cells were transfected with the indicated siRNA.  24 h later they 
were exposed to 0 – 5 Gy of ionizing radiation. 24 h later cellular DNA content was 
assessed by propidium iodide staining and flow cytometry.  Numbers in parenthesis 
indicate the percentage of all events that had a sub-G1 DNA content. 
  
Figure S6A.  Quantitation of HDM2 and p21WAF1 protein abundance from the 
experiments shown in Fig. 6A. Open bars: control; closed bars: 5 μM Nutlin-3. 
 
Figure S6B. MRC5-hTERTneo were treated with 5 μM Nutlin-3 for the indicated 
times prior to analysis by western blotting (right panel).  Left panel shows that 6 h 
treatment with Nutlin-3 does not induce HDMX-P2 mRNA in these cells, in contrast 
to MCF-7 cells. 
 
Figure S6C. MCF-7 cells were transfected with the indicated siRNA.  24 h later 5 
μM Nutlin-3 was added to the medium.  24 h later cellular DNA content was assessed 
by propidium iodide staining and flow cytometry.  Numbers in parenthesis indicate 
the percentage of all events that had a sub-G1 DNA content. 
 
Figure S6D. N-TERA-2 cells expressing the indicated shRNAs were treated with 
Nutlin-3 (10 µM) for 20 hrs. RNA and proteins were extracted and expression of 
mRNAs and proteins investigated by RT-PCR and Western blotting. 
 
 








Table S1.  
  
Chromatin IP  
Hdmx-P2 forward 5'-ATCAGTTGGAGGTTGGAGCGT-3' 
Hdmx-P2 reverse 5'-CCTCAGGTGAAGGCTGAAACA-3' 
  
Hdm2-P2 forward 5'-CGGGAGTTCAGGGTAAAGGT-3' 
Hdm2-P2 reverse 5'-AGCAAGTCGGTGCTTACCTG-3' 
  
Human P21WAF1; forward 5'-GCGGCGCGGTGGGCCGAGCGCGGG-3' 
Human P21WAF1; reverse 5'-GGCTCCACAAGGAACTGACT-3' 
  
Mdmx-P2; forward 5'-GCTAATAGGGAAGCAGCAGTGTTGGT-3' 
Mdmx-P2; reverse 5'-ACAGGTTTGGACATGTTCCATC-3' 
  
Mdm2-P2;  forward 5'- GGTGCCTGGTCCCGGACTCGC-3' 
Mdm2-P2; reverse 5'-AGAGGGTCCCCCAGGGGTGTC-3' 
  
Mouse p21WAF1; forward 5'-CCT TTC TAT CAG CCC CAG AGG ATA-3' 
Mouse p21WAF1; reverse 5'-GGG ACA TCC TTA ATT ATC TGG GGT-3'  
  
Semi-quantitative RT-PCR  
Hdmx ex1; forward 5’-GCCCTAGGATCTGTGACTGC-3’ 
Hdmx ex1β; forward; #1 5'-GATATGCAGAACCTCAGC-3' 
Hdmx ex1β; forward; #2 5'-TGTTTCAGCCTTCACCTGAG-3' 
Hdmx ex2; reverse 5’-AGATCCTGCAAGCACTGTCA-3’ 
Hdmx ex3; forward 5'-TGCATGCAGCAGGTGCG-3' 
Hdmx ex8; reverse 5'-CATTACTTCTAGGTGTAT-3'  
Hdmx ex11; reverse 5’-AGCCCCAGCCTTCTTTAGTC-3’ 
  
Hdm2 ex1; forward 5'-CCCTGTGTGTCGGAAAGATGG-3' 
Hdm2 ex2; forward 5'-CGCACGCCACTTTTTCTCTGC-3' 
Hdm2 ex11; reverse 5'-CTCTCCCCTGCCTGATACACA-3' 
  
gapdh; forward 5'-AATCCCATCACCATCTTCC-3' 
gapdh; reverse 5'-ATGAGTCCTTCCACGATACC-3' 
  
mdmx ex1; forward 5'-TCAAAATGCAGTGCAGG-3' 
mdmx ex1β; forward 5'-CTGAGGGACACTTGGCTGGT-3' 
mdmx ex9; reverse 5'-CTAATTGCTCTGACACGG-3' 
  
mouse p21WAF1; forward 5'-GTGATTGCGATGCGCTCATG 
mouse p21WAF1; reverse 5'-TCTCTTGCAGAAGACCAATC-3' 
  
mouse actin; forward 5'-GTGGGCCGCTCTAGGCACCAA-3' 
mouse actin; reverse 5'-CTCTTTGATGTCACGCACGATTTC-3' 
  
real-time RT-PCR  
Hdmx-P2; forward 5'-GATATGCAGAACCTCAGCAAGG-3' 
Hdmx-P2; reverse 5'-CCTGCAAGCACTGTCAGATGT-3' 
  
Human p21WAF1; forward 5'-AGCAGAGGAAGACCATGTGGA-3' 
Human p21WAF1; reverse 5'-AATCTGTCATGCTGGTCTGCC-3' 
  
mdmx total; forward 5'-TGACATCACATTCCACCTCGG-3' 
mdmx total; reverse 5'-ATGGTGAATACTTCCCCCTGC-3' 
  
mdmx P2; forward 5'-GGACACTTGGCTGGTTTAGTTT-3' 
mdmx-P2; reverse 5'-CGAGGTGGAATGTGATGTCA-3' 
  
mouse p21WAF1; forward 5'-CCTGACAGATTTCTATCACTCCA-3' 
mouse p21WAF1; reverse 5'-AGGCAGCGTATATCAGGAG-3' 
  
human CAPNS1; forward 5'-ATGGTTTTGGCATTGACACATG-3'  
human CAPNS1; reverse 5'-GCTTGCCTGTGGTGTCGC-3'  
  
human TBP; forward 5'-CACGAACCACGGCACTGATT-3'  
human TBP; reverse 5'-TTTTCTTGCTGCCAGTCTGGAC-3'  
  
mouse gapdh; forward 5'-TCA CCA CCA TGG AGA AGG C-3' 
mouse gapdh; reverse 5'-GCT AAG CAG TTG GTG GTG CA-3' 
 
